Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines

Journal of Bone and Joint Surgery

Volumn 92, Issue 1, 2010, Pages 162-168

  Zwolak, Pawel ^a   Manivel, J Carlos ^a   Jasinski, Piotr ^b   Kirstein, Mark N ^c   Dudek, Arkadiusz Z ^b   Fisher, James ^c   Cheng, Edward Y ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE CEMENT; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; BONE; CARCINOMA CELL; CELL VIABILITY; CYTOTOXICITY; DOSE RESPONSE; DRUG RELEASE; GIANT CELL TUMOR; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MULTIPLE MYELOMA; PRIORITY JOURNAL; TUMOR GROWTH; CELL PROLIFERATION; DRUG EFFECT; TUMOR CELL LINE;

BONE CEMENTS; BONE DENSITY CONSERVATION AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHOSPHONATES; HUMANS; IMIDAZOLES;

EID: 73949153315     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.H.01679     Document Type: Article

References (36)

1. Wedin R, Bauer HC, Wersall P. Failures after operation for skeletal metastatic lesions of long bones. Clin Orthop Relat Res. 1999;358:128-39.
2. McDonald DJ, Sim FH, McLeod RA, Dahlin DC. Giant-cell tumor of bone. J Bone Joint Surg Am. 1986;68:235-42.
3. Persson BM, Wouters HW. Curettage and acrylic cementation in surgery of giant cell tumors of bone. Clin Orthop Relat Res. 1976;120:125-33.
4. Wedin R. Surgical treatment for pathologic fracture. Acta Orthop Scand Suppl. 2001;72:2p, 1-29.
5. Chien SH, Hung SH, Cheng YM, Lin GT, Lin SY, Ko CY, Chen LH, Chiang HC. Surgical treatment of pathologic fracture of the femur. Kaohsiung J Med Sci. 1997;13:556-61.
6. Ludwig H. Advances in biology and treatment of multiple myeloma. Ann Oncol. 2005;16 Suppl 2:ii106-12.
7. Agarawal JP, Swangsilpa T, van der Linden Y, Rades D, Jeremic B, Hoskin PJ. The role of external beam radiotherapy in the management of bone metastases. Clin Oncol (R Coll Radiol). 2006;18:747-60.
8. Corso A, Ferretti E, Lunghi M, Zappasodi P, Mangiacavalli S, De Amici M, Rusconi C, Varettoni M, Lazzarino M. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer. 2005;104:118-25.
9. Liao TS, Yurgelun MB, Chang SS, Zhang HZ, Murakami K, Blaine TA, Parisien MV, Kim W, Winchester RJ, Lee FY. Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res. 2005;23:203-9.
10. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist. 2007;12:1035-43. (Pubitemid 350007015)
11. Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol. 2007;24:227-30.
12. Dougall W, Chaisson M. [Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases]. Clin Calcium. 2006;16:627-35. Japanese.
13. Fili S, Karalaki M, Schaller B. Therapeutic implications of osteoprotegerin. Cancer Cell Int. 2009;9:26.
14. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13:581-9.
15. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem. 1996;65:241-69.
16. Zhang D, Udagawa N, Nakamura I, Murakami H, Saito S, Yamasaki K, Shibasaki Y, Morii N, Narumiya S, Takahashi N. The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci. 1995;108:2285-92.
17. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell. 1992;70:401-10.
18. Marshall CJ. Protein prenylation: a mediator of protein-protein interactions. Science. 1993;259:1865-6.
19. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaissé JM, Clézardin P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60:2949-54.
20. Madanagopal SG, Seligson D, Roberts CS. The antibiotic cement nail for infection after tibial nailing. Orthopedics. 2004;27:709-12. (Pubitemid 39089619)
21. Hofmann AA, Goldberg T, Tanner AM, Kurtin SM. Treatment of infected total knee arthroplasty using an articulating spacer: 2-to 12-year experience. Clin Orthop Relat Res. 2005;430:125-31.
22. Greco F, de Palma L, Specchia N, Jacobelli S, Gaggini C. Polymethylmethacrylate-antiblastic drug compounds: an in vitro study assessing the cytotoxic effect in cancer cell lines - a new method for local chemotherapy of bone metastasis. Orthopedics. 1992;15:189-94.
23. Wang HM, Galasko CS, Crank S, Oliver G, Ward CA. Methotrexate loaded acrylic cement in the management of skeletal metastases. Biomechanical, biological, and systemic effect. Clin Orthop Relat Res. 1995;312:173-86.
24. Kim HS, Park YB, Oh JH, Yoo KH, Lee SH. The cytotoxic effect of methotrexate loaded bone cement on osteosarcoma cell lines. Int Orthop. 2001;25:343-8.
25. Weber KL, Doucet M, Price JE. Renal cell carcinoma bone metastasis: epidermal growth factor receptor targeting. Clin Orthop Relat Res. 2003;415 Suppl:S86-94.
26. Rao BM, Srinivasu MK, Rani ChP, Kumar SS, Kumar PR, Chandrasekhar KB, Veerender M. A validated stability indicating ion-pair RP-LC method for zoledronic acid. J Pharm Biomed Anal. 2005;39:781-90. (Pubitemid 41196099)
27. Marks KE, Nelson CL, Lautenschlager EP. Antibiotic-impregnated acrylic bone cement. J Bone Joint Surg Am. 1976;58:358-64.
28. Holm NJ. The modulus of elasticity and flexural strength of some acrylic bone cements. Acta Orthop Scand. 1977;48:436-42.
29. Healey JH, Shannon F, Boland P, DiResta GR. Polymethylmethacrylate to stabilize bone and deliver antineoplastic and antiresorptive agents. Clin Orthop Relat Res. 2003;415 Suppl:S263-75.
30. Zhang FL, Kirschmeier P, Carr D, James L, Bond RW, Wang L, Patton R, Windsor WT, Syto R, Zhang R, Bishop WR, Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem. 1997;272:10232-9.
31. Swanson KM, Hohl RJ. Anti-cancer therapy: targeting the mevalonate pathway. Curr Cancer Drug Targets. 2006;6:15-37.
32. Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell. 1989;57:1167-77.
33. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003;9:2643-58.
34. Knight LA, Conroy M, Fernando A, Polak M, Kurbacher CM, Cree IA. Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay. Anticancer Drugs. 2005;16:969-76.
35. Green JR. Bisphosphonates: preclinical review. Oncologist. 2004;9 Suppl 4:3-13.
36. Avcu F, Ural AU, Yilmaz MI, Ozcan A, Ide T, Kurt B, Yalcin A. The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane. Eur J Haematol. 2005;74:496-500.